Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies; Deal Terms Were Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Cosette Pharmaceuticals has acquired Vyleesi, a bremelanotide injection product, from Palatin Technologies. The financial terms of the deal have not been disclosed.
January 03, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Palatin Technologies has sold its Vyleesi product to Cosette Pharmaceuticals. The terms of the deal were not disclosed, leaving the financial impact on PTN unclear.
The sale of Vyleesi could be material for PTN, but without financial details, it's difficult to predict the exact impact on the stock price. The deal could be seen as positive if Vyleesi was not a core asset or if the sale allows PTN to focus on more promising areas. However, if Vyleesi was a significant revenue driver, the sale might be viewed negatively. The lack of disclosed terms adds uncertainty, hence a neutral score is given.
CONFIDENCE 60
IMPORTANCE 70
RELEVANCE 80